Ponatinib: A New Tyrosine Kinase Inhibitor for the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Annals of Pharmacotherapy

Volumn 47, Issue 11, 2013, Pages 1540-1546

  Shamroe, Caitlin L ^a   Comeau, Jill M ^b  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

acute lymphoblastic leukemia; ALL; AP24534; BCR ABL tyrosine kinase inhibitors; chronic myeloid leukemia; CML; Iclusig; ponatinib

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYCLOPHOSPHAMIDE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; IMATINIB; NILOTINIB; PANCREAS ENZYME; PONATINIB; POSACONAZOLE; TRIACYLGLYCEROL LIPASE; VINCRISTINE; VORICONAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AREA UNDER THE CURVE; ARTERY THROMBOSIS; ARTHRALGIA; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); CYTOGENETICS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; HUMAN; INFORMATION; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MULTIPLE CYCLE TREATMENT; MUTATION; PANCREATITIS; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALL; AP24534; BCR-ABL TYROSINE KINASE INHIBITORS; CHRONIC MYELOID LEUKEMIA; CML; ICLUSIG; PONATINIB;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDAZINES;

EID: 84889042540     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013501144     Document Type: Review

References (30)

1. Druker BJDevita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 8th ed.Philadelphia, PA: Lippincott, Williams and Wilkins; 2007:2267-2304.DeVita VTLawrence TSRosenberg SA, ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2007:2267-2304.
2. Pui C,Relling MV,Downing J.Acute lymphoblastic leukemia.N Engl J Med. 2004;350:1535-1548.
3. Deininger M,O'Brien SG,Guilhot F, et al.International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (abstract).Blood. 2009;114:1126.
4. Kantarjian H,O'Brien S,Jabbour E, et al.Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.Blood. 2012;119:1981-1987.
5. Vardiman JW,Melo JV,Baccarani M, et alWorld Health Organization of Tumours of Haematopoietic and Lymphoid Tissues. 1 positive. In: SwerdlowSHCampoEHarrisNL, eds. World Health Organization of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed.Lyon, France: IARC Press; 2008:180-182.Swerdlow SHCampo EHarris NL, ed. Lyon, France: IARC Press; 2008:180-182.
6. Druker BJ,Guilhot F,O'Brien SG, et al.Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.N Engl J Med. 2006;355:2408-2417.
7. Quintas-Cardama A,Cortes J.Chronic myeloid leukemia in the tyrosine inhibitor era: what is the best therapy?.Curr Oncol Rep. 2009;11:337-345.
8. National Comprehensive Cancer Network. Chronic myelogenous leukemia. www.nccn.org/professionals/physicians_gls/pdf/cml.pdf. Accessed March 1, 2013.
9. Delannoy A,Delabesse E,Lheritier V, et al.Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study.Leukemia. 2006;20:1526-1532.
10. Thomas DA,Kantarjian HM,Cortes JE, et al.Outcome after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) [abstract].J Clin Oncol. 2008;26:7019.
11. Yanada M,Takeuchi J,Sugiura I, et al.Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy.Haematologica. 2008;93:287-290.
12. National Comprehensive Cancer Network. Acute lymphoblastic leukemia. www/nccn/org/professionals/physicians_gls/pdf/all.pdf. Accessed April 24, 2013.
13. FDA/CEDR resources page. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist. Accessed February 29, 2013.
14. Zhou T,Commodore L,Huang W, et al.Structural mechanism of the pan-BCR-ANL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.Chem Biol Drug Des. 2011;77:1-11.
15. Zuccotto F,Ardini E,Casale E,Angiolini M.Through the "gatekeeper door": exploiting the active kinase formation.J Med Chem. 2010;53:2681-2694.
16. O'Hare T,Shakespeare WC,Zhu X, et al.AP24534, a pan-BCR-ABL, inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.Cancer Cell. 2009;16:401-12.
17. Deininger M.Optimizing therapy of chronic myeloid leukemia.Exp Hematol. 2007;35:144-154.
18. FDA/CEDR resources page. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist. Accessed February 29, 2013.
19. Cambridge, MA: ARIAD Pharmaceuticals, Inc; 2012:.
20. Cortes JE,Kantarjian H,Shah NP, et al.Ponatinib in refractory Philadelphia chromosome-positive leukemias.N Engl J Med. 2012;367:2075-2088.
21. Cortes JE,Kim DW,Pinilla-Ibarz J, et al.A pivotal phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 12-month follow-up of the PACE trial [abstract].Blood. 2012;120:163.
22. ClinicalTrials.gov; M D Anderson Cancer Center. Hyper-CVAD and ponatinib in Ph-positive and/or BCR-ABL positive acute lymphoblastic leukemia (ALL). http://www.clinicaltrials.gov/show/NCT01424982 NLM Identifier: NCT01424982. Accessed July 31, 2013.
23. ClinicalTrials.gov; Gruppo Italiano Malattie Ematologiche dell'Adulto. Phase II Front-line treatment of Philadelphia positive (Ph+)/BCR-ABL positive acute lymphoblastic leukemia (ALL) with AP24534 (Ponatinib), a new potent tyrosine kinase inhibitor (TKI): a phase II exploratory multicentric study in patients more than 60 years old or unfit for a program of intensive chemotherapy and stem cell transplantation. http://www.clinicaltrials.gov/show/NCT01641107 NLM Identifier: NCT01641107. Accessed March 6, 2013.
24. ClinicalTrials.gov; ARIAD Pharmaceuticals. Ponatinib in newly diagnosed chronic myeloid leukemia (CML) (EPIC). http://www.clinicaltrials.gov/show/NCT01650805 NLM Identifier: NCT01650805. Accessed March 6, 2013.
25. Kantarjian H,Kim DW,Pinilla-Ibarz J, et al.Efficacy and safety of ponatinib in patients with accelerated phase or blast phase chronic myeloid leukemia (AP-CML or BP-CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): 12-month follow-up of the PACE trial [abstract].Blood. 2012;120:915.
26. Cambridge, MA: ARIAD Pharmaceuticals, Inc; 2013:.
27. Red book Micromedex. Ponatinib. http://www.micromedexsolutions.com.ezproxy.ttuhsc.edu/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/DA7C16/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/8B9372/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/evidencexpert.ShowRedBookSearchResultsForActiveIngredient?SearchTerm=Ponatinib+Hydrochloride. Accessed March 11, 2013.
28. Red book Micromedex. Imatinib. http://www.micromedexsolutions.com.ezproxy.ttuhsc.edu/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/C7FD77/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/8C6C96/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/evidencexpert.ShowRedBookSearchResultsForActiveIngredient?SearchTerm=Imatinib+Mesylate. Accessed March 11, 2013.
29. Red book Micromedex. Dasatinib. http://www.micromedexsolutions.com.ezproxy.ttuhsc.edu/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/2CADD7/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/6F3765/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/evidencexpert.ShowRedBookSearchResultsForActiveIngredient?SearchTerm=Dasatinib. Accessed March 11, 2013.
30. Red book Micromedex. Nilotinib. http://www.micromedexsolutions.com.ezproxy.ttuhsc.edu/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/D04DE8/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/7DA80B/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/evidencexpert.ShowRedBookSearchResultsForActiveIngredient?SearchTerm=Nilotinib+Hydrochloride. Accessed March 11, 2013.